Azenta Inc (AZTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Azenta Inc (AZTA) has a cash flow conversion efficiency ratio of 0.012x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($20.85 Million) by net assets ($1.71 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Azenta Inc - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Azenta Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AZTA liabilities breakdown for a breakdown of total debt and financial obligations.
Azenta Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Azenta Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bittium Oyj
HE:BITTI
|
0.042x |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SHE:300619
|
0.174x |
|
Hagerty Inc
NYSE:HGTY
|
0.039x |
|
Dongguan Mentech Optical & Magnetic Co Ltd
SHE:002902
|
-0.090x |
|
EUREKA FORBES LTD
NSE:EUREKAFORB
|
N/A |
|
BTS Group Holdings Public Company Limited
BK:BTS
|
0.014x |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
N/A |
|
Kyobo Securiti
KO:030610
|
-0.082x |
Annual Cash Flow Conversion Efficiency for Azenta Inc (1994–2025)
The table below shows the annual cash flow conversion efficiency of Azenta Inc from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see Azenta Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $1.73 Billion | $72.18 Million | 0.042x | +48.47% |
| 2024-09-30 | $1.77 Billion | $49.74 Million | 0.028x | +1121.63% |
| 2023-09-30 | $2.53 Billion | $5.83 Million | 0.002x | +101.66% |
| 2022-09-30 | $3.36 Billion | $-466.05 Million | -0.139x | -222.55% |
| 2021-09-30 | $1.33 Billion | $149.86 Million | 0.113x | +262.40% |
| 2020-09-30 | $1.21 Billion | $37.87 Million | 0.031x | -60.89% |
| 2019-09-30 | $1.14 Billion | $90.90 Million | 0.080x | -22.57% |
| 2018-09-30 | $717.83 Million | $73.96 Million | 0.103x | -34.93% |
| 2017-09-30 | $607.64 Million | $96.22 Million | 0.158x | +121.71% |
| 2016-09-30 | $553.69 Million | $39.55 Million | 0.071x | +3.24% |
| 2015-09-30 | $632.04 Million | $43.73 Million | 0.069x | -17.30% |
| 2014-09-30 | $642.89 Million | $53.78 Million | 0.084x | -2.69% |
| 2013-09-30 | $632.66 Million | $54.39 Million | 0.086x | +54.89% |
| 2012-09-30 | $649.30 Million | $36.04 Million | 0.056x | -67.16% |
| 2011-09-30 | $518.60 Million | $87.65 Million | 0.169x | +136.10% |
| 2010-09-30 | $389.35 Million | $27.87 Million | 0.072x | +140.50% |
| 2009-09-30 | $319.62 Million | $-56.49 Million | -0.177x | -802.04% |
| 2008-09-30 | $542.40 Million | $13.66 Million | 0.025x | -70.28% |
| 2007-09-30 | $860.24 Million | $72.87 Million | 0.085x | +3.89% |
| 2006-09-30 | $799.53 Million | $65.19 Million | 0.082x | -18.53% |
| 2005-09-30 | $310.89 Million | $31.11 Million | 0.100x | +254.67% |
| 2004-09-30 | $313.81 Million | $8.86 Million | 0.028x | +109.52% |
| 2003-09-30 | $162.99 Million | $-48.33 Million | -0.297x | -64.47% |
| 2002-09-30 | $308.73 Million | $-55.66 Million | -0.180x | -470.36% |
| 2001-09-30 | $424.93 Million | $20.68 Million | 0.049x | +253.31% |
| 2000-09-30 | $415.04 Million | $-13.18 Million | -0.032x | -182.90% |
| 1999-09-30 | $143.60 Million | $5.50 Million | 0.038x | +159.17% |
| 1998-09-30 | $121.80 Million | $1.80 Million | 0.015x | +199.16% |
| 1997-09-30 | $134.20 Million | $-2.00 Million | -0.015x | +64.02% |
| 1996-09-30 | $50.70 Million | $-2.10 Million | -0.041x | +76.53% |
| 1995-09-30 | $40.80 Million | $-7.20 Million | -0.176x | -164.71% |
| 1994-09-30 | $4.50 Million | $-300.00K | -0.067x | -- |
About Azenta Inc
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, in… Read more